Cost–Utility of First-Line Actinic Keratosis Treatments in Finland by Erkki J. Soini et al.
ORIGINAL RESEARCH
Cost–Utility of First-Line Actinic Keratosis Treatments
in Finland
Erkki J. Soini . Taru Hallinen . Anna-Leena Sokka . Kari Saarinen
To view enhanced content go to www.advancesintherapy.com
Received: April 9, 2015 / Published online: May 26, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Cost–utility assessment of first-
line actinic keratosis (AK) treatments for max
25 cm2 AK field.
Methods: A probabilistic, 2-year decision tree
model was used to assess costs, quality-adjusted
life-years (QALY), incremental cost-
effectiveness ratio (ICER), cost-effectiveness
efficiency frontier, cost-effectiveness
acceptability frontier (CEAF), and expected
value of perfect information (EVPI) of AK
treatments from the Finnish health care payer
perspective with 3% discounting per annum. In
the model, the first-line AK treatment resulted
in complete clearance (CC) or non-CC with or
without local skin responses (LSR), or AK
recurrence. Non-CC AK was treated with
methyl aminolevulinate ? photodynamic
therapy (MAL ? PDT), and AK recurrence was
retreated with the previous effective treatment.
Costs included primary and secondary health
care, outpatient drugs, and LSR management.
QALYs were assessed with the EuroQol (EQ-5D-
3L). Result robustness was assessed with
sensitivity analyses.
Results: The mean simulated per patient
QALYs (costs) were 1.526 (€982) for
MAL ? PDT, 1.524 (€794) for ingenol mebutate
gel (IngMeb) 0.015% (3 days), 1.522 (€869) for
IngMeb 0.05% (2 days), 1.520 (€1062) for
diclofenac 3% (12 weeks), 1.518 (€885) for
imiquimod 3.75% (6 weeks), 1.517 (€781) for
imiquimod 5% (4/8 weeks), and 1.514 (€1114)
for cryosurgery when treating AK affecting any
body part. IngMeb 0.015% was less costly and
more effective (dominating) than other AK
treatments indicated for face and scalp area
with the exception of imiquimod 5% for which
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the ICER was estimated at €1933/QALY gained
and MAL ? PDT, which had an ICER of €82,607/
QALY gained against IngMeb 0.015%. With
willingness-to-pay €2526–18,809/QALY gained,
IngMeb 0.015% had[50% probability for cost-
effectiveness on the CEAF. IngMeb 0.05%
dominated AK treatments indicated for trunk
and extremities. EVPIs for face and scalp (trunk
and extremities) analyses were €26 (€0), €86
(€58), and €250 (€169) per patient with the
willingness-to-pay of €0, €15,000, and €30,000
per QALY gained, respectively.
Conclusion: IngMebs were cost-effective AK
treatments in Finland.
Funding: LEO Pharma.
Keywords: Actinic keratosis; Cost-
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INTRODUCTION
Actinic keratosis (AK) is a common pre-
malignant skin disease that impairs patients’
quality of life (QoL) [1–4] and causes a
significant burden to the health care system
[5–9]. A key cause for AK is cumulative exposure
to ultraviolet light. Clinically, AK is described as
‘‘keratotic macules, papules or plaques with
superficial scales on a red base’’ [2].
The prevalence of AK is 11–25% worldwide
[10–12]. The largest AK prevalence has been
reported in the southern hemisphere [13, 14], in
populations near the equator and in countries
with a high proportion of white inhabitants [2].
AK’s prevalence increases with age, for example,
34% and 18% of males and females over the age
of 70 had AK in the United Kingdom (UK),
respectively [11]. Histologically, AKs are
considered to be precursors of squamous cell
carcinoma (SCC), because AK can regress,
persist unchanged or progress to invasive SCC
[2, 15]. Over a decade, 1–16% of AKs progress to
invasive SCC [2].
The incidence of SCC has increased [16, 17].
In Finland, this increase has been 2.5% per
annum [15] and there were 1366 registered new
cases of SCC in Finland in 2009 [18]. Non-
melanoma skin cancer (NMSC, including SCC
and also basal cell carcinoma of the skin) is
among the top five most costly cancers [19] and
a major cost driver for health care [9, 20]. Based
on Finnish hospital discharge register (FHDR)
[21] data with nationwide public health care
coverage from 2009, around 19% of incident
NMSCs were histologically confirmed SCCs in
Finland. 18% of these histologically confirmed
SCC patients had an AK diagnosis during the
past 10 years.
Actinic keratosis lesions are commonly
located on the head (75% based on the
incident FHDR data from 2009). Typically,
multiple lesions are present in a field of UV-
damaged skin with subclinical lesions
surrounding visible lesions (so-called field
cancerization) [2, 9, 15]. SCC risk is higher in
patients with more than five AK lesions [22].
However, SCC development is impossible to
predict. It is recommended that multiple AK
lesions are treated with field treatment that can
target both visible and subclinical lesions [2, 12,
15, 23–31].
The goal of AK treatment is to achieve
complete clearance (CC) of lesions, thereby
potentially preventing the AK lesions from
developing into SCC [15, 32]. Finnish AK
articles have been published [9, 15, 33–37]
and, generally speaking, Finnish treatment
practice seems to be in line with European
approaches [2, 38] with one exception:
5-fluorouracils (5-FU) are not commonly used
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in Finnish clinical practice. Currently, only
intravenous 5-FUs are available in the Finnish
market, whereas 5-FU topical is not reimbursed
by the Finnish Social Insurance Institution and
they do not have listed prices. In Finland,
commonly used AK treatments include
cryosurgery for head (face or scalp) or body
(trunk or extremities), topical 5% imiquimod
(Aldara, head area indication) for 4 or 8 weeks
depending on the 4-week treatment response,
and methyl aminolevulinate (Metvix, head
area indication) ? photodynamic therapy
(MAL ? PDT) [37]. Diclofenac (Solaraze) 3%
for 12 weeks is used less frequently [37] and is
generally considered for older or
institutionalized AK patients in Finland.
Newer topical AK treatments include a
6-week treatment with 3.75% imiquimod
(Zyclara, head area indication), and 3- or
2-day treatments with ingenol mebutate gel
(IngMeb, Picato) 0.015% for head area or
0.05% for body area, respectively [9, 15].
IngMeb is a pleiotropic effector with a dual
action mechanism and short treatment
duration. IngMeb-associated skin reactions
typically resolve within 2–4 weeks depending
on the treated area [39–50].
Our study seeks to assess the cost–utility of
common first-line treatments for AK field (max.
25 cm2) affecting any body part. The cost-
effectiveness of AK treatments has not been
previously assessed in the Finnish context.
Furthermore, to our knowledge, our analysis is
the first to include imiquimod 3.75% and
IngMebs.
METHODS
Cost–utility analysis (CUA) is a health economic
evaluation method simultaneously comparing
both costs and quality-adjusted survival
(quality-adjusted life-years, QALY) gained with
different treatment options. The key outcome
of a CUA is incremental cost-effectiveness ratio
(ICER), the ratio of cost and QALY differences
between the treatment options given as €/QALY
gained. Cost-effectiveness is assessed in relation
to the willingness-to-pay (WTP) for additional
QALY. In the Finnish setting, the interpretation
of cost-effectiveness is complicated by the fact
that the WTP threshold used for decision
making has not been publicly announced.
Based on our experience, the maximum
threshold for AK may be around €30,000/
QALY gained, and values below €15,000/QALY
gained are likely to indicate a very good cost-
effectiveness.
For this assessment, the mean cost and
effectiveness results for each treatment
alternative were graphed on the cost-
effectiveness plane with payer costs (resources)
plotted on the horizontal axis and QALYs
(outcomes) on the vertical axis. The cost-
effectiveness efficiency frontier (CEEF) was
then drawn to depict the non-dominated
treatment alternatives. In the CEEF, a purely
dominant treatment is both more effective and
less costly in comparison to an alternative
treatment. If a combination of treatments is
more effective and less costly than an
alternative treatment, the alternative
treatment is then extendedly dominated by
the combination of treatments. Lastly, if a
treatment is more effective and more costly in
comparison to an alternative treatment, the
acceptance of a more effective and costly
treatment is based on the decision maker’s
WTP (e.g., €/QALY gained).
The significance of QALY and cost
differences between treatments was assessed
conservatively by estimating 0.25–0.75
percentiles for the QALY and cost differences
between treatments in the performed 2000
model simulations. The difference was
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considered significant, if zero was not within
the 0.25–0.75 percentiles.
Setting
Cost–utility analysis was done on the basis of
the direct impact that the compared treatments
had on the max 25 cm2 AK field, adverse events
(based on local skin responses [LSR]) and the
probability of AK’s recurrence after successful
treatment. Due to the uncertainty regarding the
impact of different AK treatments on SCC
incidence and consequent mortality, a
24-month analytical time horizon (not
including SCC development and mortality)
was considered adequate. Since the recurrence
of AK lesions after treatment response was
expected to occur within 12 months of the
primary response (e.g., [46]), the 24-month
timeframe was anticipated to fully capture the
costs, health benefits and LSRs associated with
AK treatments.
The base case analysis was conducted from
the public health care payer perspective,
considering the direct health care costs related
to AK and its management in line with the
Finnish [51] and most international guidelines
(e.g., [52–61]) on performing health economic
assessments. Following the Finnish guidance,
results were discounted by 3% per annum. The
analysis in this article was based on previously
conducted studies, and did not involve any new
studies of human or animal subjects performed
by any of the authors.
Cost-Effectiveness Model
A sequential, probabilistic, 2-year decision tree
model (Fig. 1) in Microsoft Office Professional
2007 Excel version 12 was used to carry out the
CUA. CUAs are unavoidable simplifications of
complex reality, and some assumptions were a
necessity due to data scarcity and for simplicity.
Based on the Finnish clinical expertise, incident
FHDR data, reimbursement data of the Social
Insurance Institutionof Finland, andrecent local,
national (e.g., [9, 15]) and international expert
opinions (e.g., [62]), the following structural
assumptions were made in the assessment. In
the model, the treatments resulted in CC or non-
CC after 6 months, and both outcomes could be
achieved with or without short-term LSRs. In the
case of CC, a patient was at risk of recurrence at
12 months. Non-CC AK was assumed to be
treated with MAL ? PDT whereas first-line AK
recurrence after CC was retreated with the
previous effective treatment.
Efficacy and Safety Inputs
Health effects included in the CUA were CC,
time to CC, safety in terms of LSR risks and
durations, recurrences, and QoL. CC inputs (AK
affecting any body part) were based on random
effects results of a Bayesian network meta-
analysis [63] (Supplementary Appendix 1). LSR
and recurrence probabilities were pooled trial
results (Table 1) based on the meta-analysis
material. For LSR assessment, studies with a
very low number of patients (\8 patients/
treatment arm) or reporting only serious
adverse events were excluded.
Quality of Life Inputs
Quality of life scores were applied to patients for
the duration of the model. AK and LSRs have a
detrimental effect on QoL, whereas successful
treatment leads to improvements, the
magnitude of which will depend on whether
the patient achieves CC [1, 4]. At the time of
analysis, the QoL scores by Wilson et al. [3] were
most representative values found for the
different AK states included in the model.
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Fig. 1 Simpliﬁed presentation of the 2-year decision tree
model (in addition to the 6-month complete clearance and
12-month recurrence status, the model included short-term
treatment-related adverse events). Dashed arrows show the
path of third treatment line (not considered in the base case
analysis). AK actinic keratosis
Table 1 Clinical inputs by treatment








Cryosurgery 1.693 2.5 42.0a 0.0 0.0 90.0h
Diclofenac 3% 1.660 16.0 43.0b 4.0 4.0 39.0j
Imiquimod 3.75% 2.208 10.0 40.0c 8.0 7.5 39.0j
Imiquimod 5% 4 weeks 3.238 8.0 64.0d 6.0 5.5 39.0i
Imiquimod 5% 8 weeks 2.347 12.0 64.0d 10.0 9.5 39.0i
IngMeb 0.015% 3.098 3.0 30.0e 2.5 2.0 53.9e
IngMeb 0.05% 2.182 4.0 23.0e 3.5 3.0 50.0e
MAL ? PDT 5.517 2.5 66.0f 1.0 1.0 24.0k
Second-line treatmentg 5.517 2.5 66.0 1.0 1.0 24.0
CC complete clearance, LSR local skin response, LOR log odds ratio, IngMeb ingenol mebutate gel, MAL ? PDT methyl
aminolevulinate photodynamic therapy
Pooled trial results based on: a [64–71], b [72–76], c [77, 78], d [76, 79–86], e [45], total LSRs, f [64–66, 68, 87–91],
g MAL ? PDT after topicals, h [92, 93], i [80, 94], j Imiquimod 5% (assumption), k [89, 91]
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The QoL scores of Wilson et al. [3] were
anchored to Finland using the average EuroQol
(EQ-5D-3L) QoL score of 0.776 for Finnish
people aged 65–74 years [95]. This resulted in
0.776 QoL for CC and 0.765 QoL for AK (non-
CC). These values were considered to be valid
regardless of AK site, because the lesion site has
not statistically been shown to significantly
impact the QoL [96]. The applied QoL impact
of LSR was -0.085 [3] and the duration of LSRs
is given in Table 1. After LSR resolution, the
QoL was assumed to recover back to the level
experienced in the AK health state, until the
time of potential CC was reached.
Cost Inputs
The cost estimation was based on Finnish
treatment practices and guidelines [51]. Drug
costs, primary care (PC) clinician visits,
specialist visits, procedures, hospitalizations,
and LSR management were considered in the
base case analysis. Drug costs were from 1/2015
(excluding value-added tax 10%, Table 2) and
other costs were indexed with official Finnish
communal health care price index for public
services [97] to 2013 real values. Incident AK
patients (year 2009, n = 3409, 46 organ
transplant patients excluded; 61.0% women
with the mean age of 74.6 years and 39.0%
men with the mean age of 73.4 years) were
identified from the FHDR to assess AK related
2-year secondary health care costs (including
visits, hospitalizations, and procedures) in 2013
value for first-line patients initiating different
treatment regimens. Supplementary Appendix 2
shows the secondary health care resource use
and applied expected costs.
In Finland, topical AK treatments are mostly
prescribed in specialized health care (patient
enters the system through PC visit) [38]. In the
model, 2% of all topical treatments were
prescribed in the PC setting (with full
secondary care costs in order not to
underestimate the base case costs of topicals)
and the remaining 98% were prescribed in
Table 2 Drug costs based on Finnish medicines tariff (1/2015)
Treatment Drug pack Drug unit Druga
Units Price Cost (€) /Course Cost (€)
Diclofenac (3%): 2 9 daily (12 wks) 100 g 122.44 122.44 1 122.44b
Imiquimod (3.75%): 1 9 daily (6 wks) 28 sachets 125.86 4.50 28 125.86b
Imiquimod (5%): 3 9 wk (4/8 wks)c 12 sachets 72.97 6.08 12/24 72.97/145.94
IngMeb (0.015%): 1 9 daily (3 days) 3 tubes 106.54 35.51 3 106.54
IngMeb (0.05%): 1 9 daily (2 days) 2 tubes 106.54 53.27 2 106.54
Methyl aminolevulinate photodynamic therapy and cryosurgery drug costs were assumed to be included in the Finnish
hospital discharge register data (Supplementary Appendix 2)
IngMeb ingenol mebutate gel, wk week
a First-line treatment and again for the potential treatment of recurrence for the drug costs part after complete clearance
b Wholesale price for hospital product and/or non-reimbursed product; excludes signiﬁcant cost margin of the Finnish
pharmaceutical pricing scheme [98]
c Imiqimoid 5% for 4 and 8 week treatments were combined and a revisit took place for the 8-week treatment. Based on the
Finnish social insurance institution data covering all reimbursed AK treatments during year 2011, 17.5% of imiquimod 5%
users with age[55 years undergo the 8-week treatment
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specialized health care, and MAL ? PDT and
cryosurgery were administered only in the
specialized health care setting. Short-term LSRs
led to a phone contact with health care
professional in 25% of the cases. It was
assumed that no particular treatment would be
given for the LSRs, because LSRs may precede
CC and they are not commonly treated. The
indexed unit costs for the PC visit and phone
call were €116.18 and €27.46, respectively [97,
99]. After non-CC with the first-line treatment,
all patients were assumed to receive MAL ? PDT
(additional cost for PDT €418.31 based on the
FHDR). Instead, recurrent AK was always
retreated using the same initially efficacious
treatment.
Sensitivity Analyses
Cost-effectiveness acceptability frontier (CEAF)
and expected value of perfect information
(EVPI) were selected to demonstrate the
parameter uncertainty in the base case
modeling. The CEAF shows the optimal
treatments with the highest expected net
benefit as the function of WTP. The EVPI
demonstrates the monetary value of parameter
uncertainty that can be resolved by acquiring
additional evidence for the model parameters
(the value of optimal parameter evidence) or
alternatively the expected consequences of the
wrong decision (the opportunity costs) in
monetary terms. The EVPI for each simulation
(here 2000) can be calculated row-by-row as the
net monetary benefit lost (between the optimal
treatment for the simulation and the treatment
to be selected in decision making based on the
highest average net monetary benefit);
conditional to WTP. Then the EVPI per patient
is estimated by taking the average of 2000
simulation-based EVPIs ranging from zero
upwards; conditional to WTP. In this
probabilistic analysis, distributions (normal:
log odds ratio for CC and QoL values; gamma:
time to CC, time with LSR and costs; beta: risks
related to LSR and AK recurrence, and LSR
resource use) with known standard errors or an
assumed standard error equal to 10% of the
mean value (when true standard error was not
known) were applied.
Sensitivity analysis scenarios demonstrate
the sensitivity of the probabilistic results to
modeling assumptions. The performed
scenarios cover all model inputs with
importance. The scenarios include
methodological, treatment strategy,
effectiveness and cost changes: 1 year (within-
trial for IngMebs) time horizon, no discounting
of results, rough inclusion of gender-weighted
mortality, QoL not anchored to Finland, beta
distribution for QoL values, fixed-effect meta-
analysis results for CC, similar incidence (30%
assumed) and duration (4 weeks assumed) of
LSRs for the treatments, inclusion of topical
treatment discontinuation (20% for
imiquimod, 10% for other topicals), similar
recurrence of AK after successful treatment
(50% assumed), MAL ? PDT assumed for the
recurrence treatment, active recurrence
treatment after AK CC with the second-line
treatment, third-line treatment for topicals
(second-line retreatment assumed), second-line
treatments and recurrences ignored, 30%
IngMeb used in PC, all topicals used in PC,
and societal perspective. The societal
perspective sensitivity analysis also included
traveling costs to health care and productivity
losses due to AK treatment. The cost of round
trip travel was €37.53 to secondary and €7.35 to
PC in year 2014 value ([100, 101] excluding
value-added tax). The proportion of working
persons with AK was estimated based on the
FHDR AK patient’s gender-specific age
distribution (men/women: 35–44 years 1/0%,
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45–54 years 4/4%, 55–64 years 14/13%,
65–74 years 31/27%, 75–84 years 37/37%,
85 years or older 12/18%, respectively) and
gender-specific age distribution of working
people in Finland in 2011 based on the official
statistics [102], which resulted in an average
employment rate of 15% among the AK
patients. The value of a working week lost was
€773.40 based on the human capital approach
[99, 103].
RESULTS
During the 2-year time period, the mean
simulated probabilistic per patient QALYs in
decreasing QALY order and 3% annual
discounting were 1.526 (95% confidence
interval 1.524–1.528) for MAL ? PDT, 1.524
(1.522–1.525) for IngMeb 0.015%, 1.522
(1.521–1.524) for IngMeb 0.05%, 1.520
(1.518–1.521) for diclofenac, 1.518
(1.516–1.519) for imiquimod 3.75%, 1.517
(1.515–1.519) for imiquimod 5%, and 1.514
(1.512–1.515) for cryosurgery when treating AK
affecting any body part. According to the used
measure of significance (zero not included
within the 0.25–0.75 percentiles of outcome
differences), significant QALY differences in the
head area analysis were observed only for
MAL ? PDT vs. imiquimod 5%, IngMeb
0.015% vs. imiquimod 5%, and diclofenac vs.
cryosurgery. No significant QALY differences
were found in the body area analysis.
The respective payer costs were €982 for
MAL ? PDT, €794 for IngMeb 0.015%, €869 for
IngMeb 0.05%, €1060 for diclofenac, €885 for
imiquimod 3.75%, €781 for imiquimod 5%, and
€1114 for cryosurgery. Apart from IngMeb 0.015%
vs. imiquimod 5% and diclofenac vs. cryosurgery,
allbetween-treatmentcostdifferences for thehead
area were significant. Also, all between-treatment
cost differences for the body area were significant
with the exception of insignificant difference
between diclofenac and cryosurgery. Figure 2
depicts the deterministic dispersion of costs by
treatment and cost type. LSR and recurrence
management constituted a minor proportion of
total costs. Health care, retreatment and first-line
drug were the key cost drivers.
Table 3 shows the ICERs based on the
treatment indications. The CEEF for AK in face
and scalp included only two treatments:
imiquimod 5% and IngMeb 0.015% (upper
part of Fig. 3). IngMeb 0.015% dominated the
other AK treatments indicated for the face and
scalp area with the exception of imiquimod 5%
for which the ICER was estimated at €1933/
QALY gained and MAL ? PDT, which has the
ICER of €82,607/QALY gained against IngMeb
0.015% (Table 3; Fig. 3). IngMeb 0.05%
dominated other treatments indicated for
trunk and extremities as shown by the cost-
effectiveness plane in the lower part of Fig. 3.
Based on the CEAF for AK treatments with
face and scalp area indication (upper part of
Fig. 4), IngMeb 0.015% was the optimal
treatment (i.e., treatment with highest
expected net benefit) when WTP was between
€1933 and 82,607/QALY gained. IngMeb
0.015% was also potentially cost-effective (i.e.,
Fig. 2 Deterministic dispersion of 2-year actinic keratosis
treatment costs. LSR local skin responses, MAL ? PDT
methyl aminolevulinate photodynamic therapy
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optimal treatment with the probability of cost-
effectiveness[50%) with the WTPs between
€2526 and 18,809/QALY gained. None of the
treatments were potentially cost-effective when
WTP was between 18,810 and 701,081/QALY
gained. The EVPIs per patient were €26, €86,
€250, and €504 with the WTP of €0, €15,000,
€30,000, and €50,000 per QALY gained,
respectively. The respective cost-effectiveness
probabilities for IngMeb 0.015% were 43%,
54%, 41%, and 31%.
Based on the CEAF for AK treatments
indicated for trunk and extremities (lower part
of Fig. 4), IngMeb 0.05% was the optimal and a
potentially cost-effective treatment with all
plausible (e.g., €0–50,000/QALY gained) WTP
levels. The EVPIs per patient were €0, €58, €169,
€330 with the WTP of €0, €15,000, €30,000, and
€50,000 per QALY gained, respectively. The
respective cost-effectiveness probabilities for
IngMeb 0.05% were 100%, 80%, 71%, and 66%.
Sensitivity Scenarios
Probabilistic mean QALYs and costs of
sensitivity analysis scenarios are given in
Table 4. Based on the sensitivity analyses,
IngMeb 0.015% and 0.05% were generally
cost-effective. MAL ? PDT could be cost-
effective from the full societal perspective, if
the WTP per QALY gained for the societal
perspective exceeds €28,802—yet, IngMeb
0.015% dominated imiquimod 5% in the same
analysis. IngMeb 0.015% dominated
imiquimod 5% also when a 1-year time
horizon, fixed-effects meta-analysis, 30% of
IngMeb in the PC setting or all topicals in the
PC setting inputs were used.







Diclofenac Imiquimod 3.75% Imiquimod
5%
Cryosurgery
MAL ? PDT 82,607 MAL ? PDT
dominant
















na na – 100,128 Imiquimod 3.75%
dominant







Head ICERs are in the upper right side and body ICERs in the lower left side of the Table 3
Dominant the mentioned treatment dominates the comparator, ICER incremental cost-effectiveness ratio, IngMeb ingenol
mebutate gel, MAL ? PDT methyl aminolevulinate photodynamic therapy, na not applicable (one or both of the
treatments do not have the indication)
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The ICERs of MAL ? PDT vs. IngMeb 0.015%
were most sensitive to changes in LSR impact
(similar assumption for both increased the ICER
with €99,906/QALY gained in comparison to
the base case) and the proportion of topicals
prescribed in the PC (the 100% topical
prescriptions in PC basis increased the ICER
with €79,087/QALY gained).
DISCUSSION
This study compared the cost–utility of all
relevant AK treatment options for the
treatment of a 25-cm2 AK field in the Finnish
setting, and was the first to include IngMebs
and imiquimod 3.75%. Based on this study,
IngMebs can result in effectiveness (QALY)
gains at acceptable costs in their indication,
significant cost and effectiveness differences can
exist between the treatments, and treating AK
in the PC setting (where feasible) can result in
cost savings.
For face and scalp AK, MAL ? PDT was
projected to be the most effective treatment,
but its effectiveness came with high payer costs.
There was no significant difference in 2-year
effectiveness between MAL ? PDT and IngMeb
0.015%, and a high ICER of €82,706/QALY
gained was estimated for MAL ? PDT against
IngMeb 0.015%. The respective ICER was
€28,807/QALY gained in the full societal
perspective analysis—the setting which is not
recommended to be used alone without the
payer perspective [51]. Even though there are
no published ICER thresholds in Finland, it
seems that ICERs exceeding €50,000/QALY
gained are rarely considered cost-effective for
other than very severe diseases and that ICERs
should be\€20,000/QALY gained for more
common and/or less severe conditions, which
is in line with, for example, the UK thresholds
[61].
Based on this analysis, MAL ? PDT’s 2-year
payer costs should be at least 15% lower to meet
the €20,000/QALY gained. The result and
affordable tendered cost with potential drug
sharing were assumed for MAL (for topicals,
official list costs were used). Yet, in comparison
with commonly used imiquimod 5%, IngMeb
0.015% was significantly more effective and
resulted in a low ICER of €1993/QALY gained
for the face and scalp AK. The cost-effectiveness
of imiquimod 5% was, however, uncertain
because IngMeb 0.015% dominated
imiquimod 5% when a 1-year time horizon,
Fig. 3 Cost-effectiveness efﬁciency frontier (black and
dashed gray lines, upper part of ﬁgure) in cost-effectiveness
plane for actinic keratosis in head area. The lower part of
the ﬁgure shows the outcomes for body area (trunk,
extremities) treatments in the cost-effectiveness plane.
ICER incremental cost-effectiveness ratio, IngMeb ingenol
mebutate gel, MAL ? PDT methyl aminolevulinate
photodynamic therapy, QALY quality-adjusted life-year
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fixed-effects meta-analysis, MAL ? PDT for the
treatment of recurrence, 30% of IngMeb in the
PC setting, all topicals in the PC setting or the
societal perspective inputs were used.
Furthermore, IngMeb 0.05% was the most
effective and cost-saving treatment for AK in
trunk and extremities in all analyses.
Consequently, both formulations of IngMeb
were cost-effective in the Finnish setting.
The modeled results were used to assess the
value of perfect information. The EVPI per
patient can be interpreted as the maximum
average sum per patient that is worthwhile to
invest in the gathering of additional evidence
for the varying model parameters. When the per
patient EVPI of €136 for head (€93 for body)
area with €20,000/QALY gained is compared
against the potential cost of additional research
Fig. 4 CEAF and EVPI for the treatments indicated for
actinic keratosis on face and scalp (cryosurgery, diclofenac,
imiquimod 3.75%, imiquimod 5%, ingenol mebutate gel
0.015%, methyl aminolevulinate photodynamic therapy)
are presented in the upper part of the ﬁgure. The CEAF and
EVPI for actinic keratosis treatments indicated for trunk
and extremities (cryosurgery, diclofenac, ingenol mebutate
gel 0.05%) are presented in the lower part of the ﬁgure. CEAF
cost-effectiveness acceptability frontier, EVPI expected value
of perfect information QALY quality-adjusted life-year
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per studied patient, the decision on whether to
invest in additional research may not be
supported. On the other hand, if the EVPI is
interpreted as the opportunity cost for choosing
a particular optimal treatment for all patients,
and given that the optimal treatment decision
would be an incorrect one for some patients
(opportunity cost), the EVPI per patient with
€20,000/QALY gained was rather low in
comparison to, for example, costs associated
with different treatments. This also means that
it may not be worthwhile from the perspective
of cost-effectiveness to find patients to whom
the average optimal treatment is not really
optimal.
The assessment of AK field treatment was
important for several reasons. First, where
multiple AK lesions are present there is likely
to be an underlying and surrounding area of
actinic damage (field change); the extent of this
area may not be evident visually or by physical
examination. Second, field change can have a
role in the development of SCC or other NMSCs.
Third, cryotherapy is a commonly used lesion-
directed therapy that does not target actinic
changes in the sun-damaged skin surrounding
the individual lesion [2, 30]. Fourth, before
IngMeb, there was medical (adherence) need
for field directed therapies with shorter and
simpler treatment regimens and less long-term
irritation and inflammation [31].
Direct comparative data between the
relevant treatment options were not available
and thus, CCs were included on the basis of
Bayesian network meta-analysis [63]. In
comparison with one alternative meta-analysis
available [104] that includes IngMeb without
any further specification, we chose the meta-
analysis assessed by the authorities for the
following reasons: IngMeb 0.015% and 0.05%
were included and separated (they are
essentially different treatments for different
indications), and imiquimod 5% for 8 weeks
and 3.75% for 6 weeks were included. However,
on aggregate level, the results of these meta-
analyses concur, and in both analyses,
frequently used cryotherapy is inferior.
One reason for cryosurgery’s relatively poor
result can be related to the fact that primarily
destructive therapies of individual AKs do not
prevent the progression of AK into SCCs in
adjacent dysplastic tissues. According to the
European Dermatology Forum guidelines
management strategies that counteract the
effects of systemic immunosuppression via the
induction of a locally restricted, tumor-specific
immune response, the induction of apoptosis in
dysplastic keratinocytes or the use of
phototoxic agents can provide viable options
for treatment of the AK field [2].
Some studies assessing the economic value or
cost-effectiveness of treating AK with different
treatment response assessment times have been
done [3, 6, 105–113]. Generally, the treatment
of AK has been found to be cost-effective.
However, MAL ? PDT and sometimes
cryosurgery treatment have been found to be
relatively costly, which is in line with the results
of this analysis. Some of the published studies
were based on cost estimates and other
assumptions that are not applicable or
reproducible in Finnish (e.g., [110, 111]) or
other settings [113]. We included a wide
spectrum of outcomes. The average time to
assess the response was 6 months in the trials
and 6 months was also an adequate time to
assess CC based on the Finnish clinical practice.
We also accounted for the treatment specific
time to CC and time with LSR in addition to a
12 months recurrence risk. Furthermore, when
considering the European perspective of
resources used and associated costs, the
Finnish setting represents the average quite
well for skin cancers [38].
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This modeled assessment had some key
limitations. First, a decision tree approach was
chosen as a more appropriate and simpler
approach consistent with the nature of AK and
its treatments. In particular, the differential
timing of treatment responses and LSRs (and
also productivity losses in a sensitivity analysis
scenario) with different treatments had to be
considered, and was included as a distribution.
In the Markov model setting, the inclusion of
these characteristics would have necessitated a
very short cycle length (e.g., 1 week) and the
derivation of transition probabilities would
have become very difficult or impossible. It
should be noted that in conventional Markov
models, instant response to treatment is usually
assumed and the timing of events is then
‘‘adjusted’’ with, for example, a life table
method of half-cycle correction which would
not have been an unbiased approach in this AK
setting. Another valid approach in addition to
the flexible decision tree would have been a
discrete event simulation which was not
considered due to lack of patient-level data or
equations based on the patient-level data.
Second, the decision tree had a 2-year time
horizon, which was selected due to multiple
reasons. Development of SCC over time is
uncertain and it is uncertain whether the AK
treatments have similar or different impacts on
the risk of developing SCC. Furthermore, the
development of AK fields other than the initial
field would have to be accounted for. In addition,
costs of drugs can change over time, and the
effectiveness of multiple treatment times (in the
case of multiple recurrences) to the same field is
likely to decrease by the treatment line (but there
is no data to confirm this assumption which is
needed for a longer than 2-year model). In
addition, the AK patient group is rather old and
for a longer time horizon model, mortality would
have to be accounted for and currently there is no
data on whether the AK treatments impact
mortality. Consequently, we see that extension
of the time horizon would complicate the model
and require manymajorassumptionswithoutany
scientific evidence to support them. The impact of
longer time horizon to the assessment question
(the cost-effectiveness of treating a particular
25 cm2 AK field) would be marginal from the
perspective of current data, and would potentially
have a negative risk–benefit ratio (i.e., the risks
due to inherent major modeling assumptions
could potentially bias the results).
Third, the modeling assumed that treatment
responses are assessed at 6 months after
treatment. However, in real-life clinical practice,
the assessment may take place earlier; this
assumption was considered plausible since the
model accounts for the varying time to treatment
response and time with LSR when calculating
QALYs. The 6-month interval was based on the
mid-point assessment range of clinical trials that
were identified for the Bayesian network meta-
analysis [63]. Furthermore, a static time point was
required for a decision tree structure, to allow all
comparisons to be treated equally.
Fourth, patients entered the model when
initiating the first-line therapy. IngMeb has the
potential to be used more in the PC setting. For
that, a scenario with 30% PC use was assessed.
As an extreme sensitivity analysis scenario and
to improve result comparability to other
settings, all topicals were assumed to be used
in the PC setting.
Fifth, all patients were assumed to complete
the first course of treatment in the base case
analysis because the used efficacy data are based
on an intention-to-treat setting, which
therefore already incorporated the impact of
treatment discontinuations [114, 115]. Also, the
treatment response/success was measured in
terms of CC (no AK lesions remaining), which
is the strictest definition of treatment success,
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but well in line with the AK treatment
objectives. This is easy to understand and may
be a less biased outcome in comparison with,
e.g., proportion of AK lesions cleared.
Sixth, the study lacked the data for subgroup
analysis based on patient characteristics.
Hypothetically speaking, differences in QALYs
could be marginally larger for men or for
younger than average patients based on their
population values [95]. In a longer time horizon
modeling including mortality, the potential
difference between men and women is likely
to be meaningless.
Last, these estimated treatment costs and
benefits due to AK management are not
negligible. If AK could be increasingly treated
in PC, treatment costs could be significantly
reduced compared with the current situation.
Future studies should focus on the relationship
between the AK treatment outcome and NMSC,
which may further highlight the need for AK
field treatment. In other settings, the CEAs may
also include 5-FU. Furthermore, the results for
subgroups (e.g., younger and older patients,
men and women) may be regarded relevant, if
value for money is assessed based on patient
characteristics or at individual level.
CONCLUSION
IngMeb 0.015% and 0.05% resulted robustly in
quality of life gains at acceptable costs when
compared with all relevant AK treatment
options in Finland. Relatively low EVPI at €250
per patient with the maximum expected WTP
of €30,000 per QALY gained was estimated.
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